Skip to main content
CORDIS - Forschungsergebnisse der EU
CORDIS
Inhalt archiviert am 2024-05-27

The balance of ubiquitin conjugation and deconjugation

Ziel

Ubiquitin conjugation is one of the most important signaling systems in the eukaryotic cell. Different types of mono- and polyubiquitin chains determine the fate of target proteins by redirecting them for degradation, relocalization or interaction with new partners. The type of ubiquitin modification on any target is determined by the interplay between the conjugating E2/E3 complexes on the one hand and deubiquitinating enzymes on the other. In practice, it is the balance between conjugating and deconjugating systems that determines the result of the various ubiquitination signals. For three different regulatory systems that are critical for correct genome maintenance, we are now in a position to study not just the individual process of conjugation or deconjugation in isolation, but rather, reconstitute the entire reaction on a defined physiological target. These three target systems, histone H2A, PCNA and P53, can be mono-ubiquitinated by a defined E3-ligase, poly-ubiquitinated by a second ligase and deconjugated by defined deubiquitinating enzymes in a reaction that is affected by known allosteric modulators. Our unique collection of tools to study these systems in vitro allows reconstitution of the full reaction, to trap intermediates, and to study their interaction from atomic detail to kinetic reactivity. Using X-ray crystallography of critical intermediates and kinetic analysis of individual reactions by FRET and surface plasmon resonance, we can address how the mono-, poly and deubiquitinating reactions affect each other. By answering mechanistic questions on the relative effect of the forward and backward reaction components and their modulators we will provide a solid basis for drug design studies that target these pathways against cancer development.

Aufforderung zur Vorschlagseinreichung

ERC-2009-AdG
Andere Projekte für diesen Aufruf anzeigen

Gastgebende Einrichtung

STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
EU-Beitrag
€ 2 299 720,00
Adresse
PLESMANLAAN 121
1066 CX Amsterdam
Niederlande

Auf der Karte ansehen

Region
West-Nederland Noord-Holland Groot-Amsterdam
Aktivitätstyp
Research Organisations
Kontakt Verwaltung
Henri Van Luenen (Dr.)
Hauptforscher
Titia Karen Sixma (Prof.)
Links
Gesamtkosten
Keine Daten

Begünstigte (1)